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Neutralizing antibody against human papillomavirus (HPV) minor capsid protein L2 can cross-neutralize different HPV genotypes in vitro. To
identify the segments containing the cross-neutralization epitopes of HPV16 L2, we characterized antisera obtained by immunizing two rabbits
with each of the ten synthetic peptides of 14 to 20 amino acids (aa) long, which represents a part of the HPV16 L2 sequence from aa 14 to 144.
The antisera against the peptides within the region from aa 18 to 144 efficiently bound to HPV16 L1/L2-capsids and neutralized HPV16
pseudovirions, indicating that the region is displayed on the surface of the capsids and contains several neutralization epitopes. Antiserum against
the peptide from aa 18 to 38 (anti-P18/38) cross-neutralized HPV18. Anti-P56/75 cross-neutralized HPV18, 31, and 58. Anti-P61/75 and anti-P64/
81 cross-neutralized HPV18 and 58. Anti-P96/115 and the antiserum induced by a mutant P96/115 (S and T at aa 101 and 112 were replaced with
L and S, respectively) cross-neutralized HPV31 and 58. The mixture of equal volumes of three antisera, anti-P18/38, anti-P56/75, and anti-mutant
P96/115, neutralized HPV16, 18, 31, and 58 more efficiently than anti-P56/75 alone, suggesting that there is a synergistic effect of antibodies on
the cross-neutralization. The cross-neutralization appears to be correlated with conserved aa sequences among HPV types. The data in this study
provide a basis for designing vaccine antigens effective against a broader spectrum of the high-risk HPVs.
© 2006 Elsevier Inc. All rights reserved.Keywords: HPV16; Minor capsid protein L2; Neutralization epitopeIntroduction
Human papillomavirus (HPV) is a small nonenveloped virus
having an 8-kb double-stranded circular DNA. To date more
than 100 HPV genotypes, classified based on the homology of
genomic DNA, have been identified in proliferative lesions of
skin or mucosa (Stoler, 2000). HPVs that infect the genital
mucosal epithelia are divided into two groups: low-risk types
(such as types of 6 and 11) found mainly in benign condyloma
and 15 high-risk types (types of 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, 68, and 73) (Munoz et al., 2004) found in cervical
cancer, the most frequent gynecological cancer in the world
(Ferlay et al., 1998; Jones, 1999). Although the distribution of⁎ Corresponding author. Fax: +81 3 5285 1166.
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doi:10.1016/j.virol.2006.08.037high-risk HPVs in humans slightly varies from region to region,
type 16 (HPV16) accounts for about 50% of the cases worldwide
(Munoz et al., 2004).
An icosahedral HPV capsid is composed of major capsid
protein L1 and minor capsid protein L2. Since it is difficult to
obtain a large amount of HPV particles by using conventional
cell cultures, surrogate systems capable of expressing L1 and
L2 have been developed to obtain HPV capsids for structural
and immunological analysis. Expression of L1 either alone or
together with L2 in cultured cells results in production of L1
capsids (also called virus-like particle; VLP) (Kirnbauer et al.,
1992) or L1/L2-capsids (Zhou et al., 1991). The L1 capsid is
composed of 360 L1 molecules arranged as 72 pentameric
capsomeres (Baker et al., 1991; Crawford and Crawford,
1963), and the L1/L2-capsid contains additional 12 L2 mole-
cules whose N-terminal region is displayed on the surface of
Fig. 1. Synthetic peptides used as antigens for immunizing rabbits. The
potentially immunogenic segments were searched for within the HPV16 L2
surface region. The peptides having the amino acid sequences of the predicted
antigenic regions were synthesized and conjugated with keyhole limpet
hemocyanin (KLH). The numbers above the amino acid sequences are amino
acid number of HPV16 L2, which consists of 473 amino acids. The N-terminal
Cs of P56/75, P61/75, P61/75(73V), P64/81, P90/111, P96/115, P96/115(101L,
112S), and P107/122 and the C-terminal C of P131/144 were added for the C-
mediated conjugation reaction. Two rabbits were immunized with each peptide.
267K. Kondo et al. / Virology 358 (2007) 266–272the capsids (Heino et al., 1995; Liu et al., 1997). These
particles are morphologically indistinguishable by electron
microscopy from HPV virions extracted from the lesions
(Kirnbauer et al., 1992).
Expression of L1 and L2 in cells harboring episomal copies of
BPV1 genome or an expression plasmid results in packaging of
the episomal DNA into the L1/L2-capsids to produce infectious
pseudovirions (Buck et al., 2004; Roden et al., 1996; Stauffer et
al., 1998; Unckell et al., 1997; Zhao et al., 1998; Zhou et al.,
1993). Although it is not clear whether the pseudovirions are
assembled in the same way as the authentic HPV virion, the
pseudovirions are used as a surrogate virus to detect neutralizing
activity of anti-HPV antibodies.
Anti-L1 antibodies obtained by immunizing mice or rabbits
with the L1 capsids have been shown to have primarily type-
specific neutralizing activity. Limited cross-neutralizing activity
has been observed between closely related types such as HPV18
and 45, and HPV6 and HPV11 (Giroglou et al., 2001). Anti-L1
antibodies can protect animals against challenge with animal
papillomaviruses (Breitburd et al., 1995; Suzich et al., 1995).
The L1 capsids of HPV6, 11, 16, and 18 were used in the recent
clinical trials as prophylactic vaccines, which successfully
induced type-specific neutralizing antibodies in recipients
(Harper et al., 2006; Villa et al., 2005).
Anti-L2 antibodies have cross-neutralizing activity in vitro.
Roden et al. (2000) showed that the antisera obtained by
immunizing sheep with bacterially produced L2s of HPV6, 16,
and 18 neutralize the pseudovirions of homologous HPV types
and cross-neutralize those of the heterologous HPV types.
Kawana et al. (1999) showed that a mouse monoclonal antibody
recognizing a linear epitope within HPV16 amino acids (aa)
108–120 inhibits infection with HPV16 and 6 pseudovirions,
which were produced by an in vitro packaging method.
Recently, Pastrana et al. (2005) reported that antibodies to
bovine papillomavirus type 1 (BPV1) L2 aa 1–88 neutralize
HPV16, 18, and BPV1 pseudovirions and HPV11 native virions
efficiently and HPV31, 6 and cottontail rabbit papillomavirus
pseudovirions less efficiently.
Vaccination of animals with L2 protects animals from animal
papillomavirus challenge similarly to vaccination of animals
with the L1 capsids. Embers et al. (2002) showed that immu-
nization of rabbits with the peptides having amino acid
sequences of rabbit oral (ROPV) and cutaneous (CRPV)
papillomavirus L2 segments corresponding to HPV16 L2 aa
108–120 protect the rabbits from challenge with ROPV and
CRPV, respectively. The level of protection induced by these
peptides is comparable to that with L1 capsid vaccination. These
data, together with the cross-neutralization activity of anti-L2
antibody in vitro, suggest that L2-vaccine may induce antibody
protecting against a broad spectrum of the high-risk HPVs. The
detailed characterization of L2-neutralization epitopes is
required to design L2-vaccine antigens.
In this study we produced antisera by immunizing rabbits
with synthetic peptides representing segments of the HPV16 L2
surface region and examined their neutralizing activity against
HPV16 and cross-neutralizing activities against HPV18, 31,
and 58.Results and discussion
Binding of anti-L2-peptide rabbit antisera with L1/L2-capsid
We searched for potentially immunogenic segments within
the N-terminal region (amino acids [aa] 1–150) of HPV16 L2
by using a computer program (Lasergene Soft ver.6, DNA Star
Inc., Madison, WI). The peptides representing the aa sequences
of the predicted antigenic segments and three mutant peptides
(Fig. 1) were synthesized and conjugated with keyhole limpet
hemocyanin (KLH). Numbering of aa in L2 of HPV 16 is
deduced from the revised sequence of HPV16 (HPV16R)
registered in the HPV Sequence Database (Los Alamos
National Laboratory, NM). The peptide having aa sequence
corresponding to HPV16 L2 aa 14 to 27 was designated as P14/
27. The other peptides were designated similarly. Peptides P28/
42(32V, 39T) (D at aa 32 and K at aa 39 of P28/42 were
replaced with Vand T, respectively), P61/75(73V) (I at aa 73 of
P61/75 was replaced with V), and P96/115(101L, 112S) (S at aa
101 and T at aa 112 of P96/115 were replaced with L and S,
respectively) were designed to convert the original aa into those
of majority of the oncogenic HPVs. The immunization of two
268 K. Kondo et al. / Virology 358 (2007) 266–272rabbits with each of the peptide antigens induced antibodies
with binding titers of 8000 to 64,000. The binding titer was
expressed as a reciprocal of the maximum dilution of serum that
induced higher OD than that the corresponding preimmune
serum diluted at 1 to 100 did (data not shown).
Table 1 shows the bindings of the antisera that were diluted
at 1 to 500 to the L1 capsids of HPV16, the L1/L2-capsids of
HPV16, 18, 31, and 58 by ELISA. The antiserum from rabbit
#1 immunized with P-14/27 (anti-P14/27#1) did not react to
the L1/L2-capsids, but anti-P14/27#2 reacted to the L1/L2-
capsids. Because both antisera were highly reactive to P14/27,
P14/27 probably contained at least two epitopes. The epitope
recognized by anti-P14/27#1 appears not to be displayed on
the surface of the L1/L2-capsid, suggesting that the N-terminal
border between the inside and surface region of L2 is within
the segment from aa 14 to 27. The other sera against the
peptides having the authentic aa sequences of HPV16 L2 were
found to bind to HPV16 L1/L2-capsids, indicating the L2
region from aa 18 to 144 is displayed on the surface of the L1/
L2-capsids.
Anti-P56/75#1 and #2, anti-P61/75#1 and #2, anti-P64/81#1
and #2, anti-P90/111#1, anti-P96/115#1and #2 cross-bound to
the L1/L2-capsids of HPV18, 31, and 58. Anti-P90/111#2 did
not bind to the L1/L2-capsids of HPV18 and 58. It is possible
that epitope(s) recognized by anti-P90/111#2 may be different
from those recognized by anti-P90/111#1.
Although anti-P28/42 sera bound to HPV16 L1/L2-capsids
efficiently and to HPV58 L1/L2-capsids less efficiently, anti-
P28/42(32V, 39T) bound to HPV16 L1/L2-capsids with a lowTable 1
Binding of antibody to the L1/L2-capsids of HPV16, 18, 31 and 58 (absorbency











Anti-P14/27 #1 0.066 0.066 0.044 0.053 0.061
#2 0.064 0.112 0.055 0.057 0.138
Anti-P18/38 #1 0.069 0.744 0.057 0.067 0.124
#2 0.160 0.457 0.065 0.090 0.100
Anti-P28/42 #1 0.085 0.255 0.055 0.113 0.159
#2 0.084 0.547 0.061 0.091 0.156
Anti-P28/42 (32V, 39T) #1 0.093 0.106 0.058 0.075 0.053
#2 0.089 0.135 0.059 0.070 0.070
Anti-P-56/75 #1 0.068 0.951 0.717 0.807 0.514
#2 0.085 1.022 0.565 0.336 0.462
Anti-P61/75 #1 0.066 0.954 0.634 0.444 0.271
#2 0.109 0.884 0.612 0.343 0.553
Anti-P61/75 (73V) #1 0.075 0.700 0.379 0.421 0.170
#2 0.075 0.694 0.269 0.427 0.153
Anti-P64/81 #1 0.226 1.033 0.838 0.693 0.340
#2 0.112 1.029 0.647 0.717 0.205
Anti-P90/111 #1 0.104 1.049 0.367 0.561 0.265
#2 0.078 0.879 0.085 0.459 0.096
Anti-P96/115 #1 0.087 0.984 0.436 0.491 0.172
#2 0.102 1.049 0.808 0.757 0.570
Anti-P96/115 (101L, 112S) #1 0.075 0.840 0.070 0.808 0.430
#2 0.043 0.841 0.421 0.672 0.571
Anti-P107/122 #1 0.086 1.034 0.068 0.149 0.309
Anti-P131/144 #1 0.072 0.497 0.048 0.077 0.052
#2 0.119 0.921 0.056 0.064 0.072efficiency and did not bind to the L1/L2-capsids of HPV18, 31,
and 58. The result strongly suggests that D at aa 32 and K at aa
39 are associated with the epitope.
Anti-P61/75(73V)#1 and #2 and anti-P96/115(101L, 112S)
#2 bound to the L1/L2-capsids of HPV16, 18, 31, and 58,
suggesting that P61/75(73V) and P96/115(101L, 112S) have
potential to induce antibodies capable of binding to the 15
oncogenic HPVs.
Neutralization of HPV16, 18, 31, and 58 pseudovirions with
the rabbit antisera
Neutralizing activities of the antisera were measured by
inhibition of infection of 293TT cells, a human fibroblast cell
line expressing a high level of SV40 T-antigen, with infectious
HPV16, 18, 31, and 58 pseudovirions containing the SEAP
expression plasmid having the SV40 replication origin. Serum
was mixed with the pseudovirion stock and then inoculated to
293TT cells. Seventy-two hours later the SEAP activity of the
culture medium was measured. The neutralizing titer was
expressed as a reciprocal of the maximum dilution of serum that
reduced the level of SEAP activity to half of the sample not
treated with serum (Table 2).
Anti-P14/27#1 and #2 did not neutralize the pseudovirions
tested in agreement with the lack of their efficient binding to the
L1/L2-capsids (Table 1).
Anti-P18/38 neutralized HPV16 and cross-neutralized
HPV18. Although the antisera diluted at 1 to 500 did not bind
to the HPV18 L1/L2-capsids efficiently (Table 1), the antisera
bound to HPV18 pseudovirions (data not presented), suggesting
that the capsid containing DNA may be somewhat different
from the empty capsid conformationally.
Anti-P28/42#1 did not neutralize HPV16 nor cross-neutral-
ized HPV18, 31, and 58. Anti-P28/42#2, which bound to the
HPV16 L1/L2-capsids more efficiently than anti-P28/42#1
(Table 1), neutralized HPV16 and cross-neutralized HPV58.
Because anti-P28/42#1 and anti-P28/42#2 showed a similar
binding efficiency to the HPV58 L1/L2-capsid, antibodies in
these antisera probably recognized different epitopes.
Anti-P56/75#1 and #2 neutralized HPV16 and cross-
neutralized HPV18, 31, and 58. Anti-P61/75#1 and #2 and
anti-P64/81#1 and #2 neutralized HPV16 and cross-neutralized
HPV18 and 58. Based on the comparison of the aa sequences of
P56/75, P61/75, and P64/81, we speculated that P56/75 may
induced antibody recognizing the portion from aa 56 to 61, of
which aa sequences are common among the 15 oncogenic
HPVs (Fig. 2). Because anti-P61/75 and anti-P64/81 did not
cross-neutralize HPV31 despite the efficient binding to HPV31
L1/L2-capsids (Table 1), it is strongly suggested that the
binding is necessary but not sufficient for the neutralization.
Both anti-P90/111#1 and #2 neutralized HPV16, and anti-
P90/111#2 cross-neutralized HPV31. Anti-P96/115#1 and #2
neutralized HPV16. Anti-P96/115#2, which bound to the L1/
L2-capsids more efficiently than anti-P96/115#1, efficiently
cross-neutralized HPV31 and HPV58 but did not HPV18.
Anti-P107/122#1 and anti-P131/144#2 neutralized HPV16
exclusively.
Table 2
Neutralization of HPV16, 18, 31, and 58 pseudovirions with the antisera
Antiserum Neutralizing titer against
HPV16 HPV18 HPV31 HPV58
Anti-P14/27 #1 <50 <50 <50 <50
#2 <50 <50 <50 <50
Anti-P18/38 #1 800 50 <50 <50
#2 400 100 <50 <50
Anti-P28/42 #1 <50 <50 <50 <50
#2 800 <50 <50 50
Anti-P28/42,
32V, 39T
#1 <50 <50 <50 <50
#2 <50 <50 <50 <50
Anti-P56/75 #1 400 200 200 400
#2 200 50 100 200
Anti-P61/75 #1 400 100 <50 50
#2 800 200 <50 100
Anti-P61/75,
73V
#1 100 <50 <50 <50
#2 100 <50 50 <50
Anti-P64/81 #1 3200 400 <50 100
#2 800 200 <50 50
Anti-P90/111 #1 200 <50 50 <50
#2 200 <50 <50 <50
Anti-P96/115 #1 200 <50 50 <50
#2 400 <50 400 200
Anti-P96/115,
101L, 112S
#1 100 <50 200 200
#2 100 50 100 100
Anti-P107/122 #1 100 <50 <50 50
Anti-P131/144 #1 <50 <50 <50 <50
#2 200 <50 <50 <50
Table 3
Neutralization of HPV16, 18, 31, and 58 pseudovirions with the mixture of three
antisera
Mixture of antisera Neutralizing titer
HPV16 HPV18 HPV31 HPV58
Anti-P18/38 #2
Anti-P56/75 #1 1600 800 800 400
Anti-P96/115 (101L, 112S) #1
Anti-P18/38 #2
Anti-P56/75 #1 800 800 400 100
Preimmune for P96/115 (10L1, 112S) #1
Preimmune for P18/38 #2
Anti-P56/75 #1 100 50 50 50
Preimmune for P96/115 (101L, 112S) #1
Preimmune for P18/38 #2
Preimmune for P56/75 #1 <50 <50 <50 <50
Preimmune for P96/115 (101L, 112S) #1
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tions, anti-P96/115(101L, 112S) showed efficient cross-neutral-
ization. Anti-P96/115(101L, 112S)#1 neutralized HPV16, 31,
and 58. Anti-P96/115(101L, 112S)#2 neutralized the all HPVs
tested.
We selected three antisera, anti-P18/38#2, anti-P56/75#1, and
anti-P96/115(101L, 112S)#1, which showed the cross-neutraliz-
ing activity and the antigens used to obtain these antisera do not
overlap each other, mixed equal volumes of these antisera, andFig. 2. Amino acids sequences of the L2 portions, aa 18 to 38, aa 56 to 81, and aa 96
Amino acids identical to those of HPV16 were indicated by asterisk (*).the mixture's neutralizing activity was measured similarly. The
mixture neutralized HPV16, 18, 31, and 58 efficiently. When
anti-P18/38#2 and anti-P96/115(101L, 112S)#1 were replaced
with preimmune serum, neutralization activity was lowered. The
data suggest that the bindings of multiple antibodies to the L2
surface region enhance neutralization of HPVs.
In summary, the data in this study indicate that multiple
neutralization epitopes are present within the HPV16 L2 surface
region, from aa 18 to 144. It was suggested that some of the
peptide antigens having highly conserved aa sequences in the
L2 surface region among oncogenic HPVS would have a
potential to induce type common neutralization antibodies.
From the data of the neutralization tests with the mixtures of
three antisera (Table 3), it was suggested that the effective
neutralization could be achieved through the binding of multiple
antibodies to the L2 surface. It appears to be a good idea toto 115 of HPV16 and the corresponding portions of the other oncogenic HPVs.
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bodies binding to different epitopes on the L2 surface region.
Since the aa sequences of the L2 surface regions of 15
oncogenic HPVs are largely similar, it seems possible to
develop a vaccine antigen capable of inducing antibodies




293TT cells, a cell line expressing a high level of SV40
T antigen, was a kind gift from J. T. Schiller (National Cancer
Institute, USA). The cells were cultured with in Dulbecco's
modified minimal essential medium (DMEM) supplemented
with 10% fetal bovine serum, 1% non-essential amino acids
(Invitrogen Corp. Carlsbad, CA), 1% GlutaMax-I (Invitrogen
Corp.), and hygromycine B (400 μg/ml) (Invitrogen Corp.).
Plasmids
Five plasmids; pYSEAP expressing SEAP, p16L1h expres-
sing HPV16 L1, p16L2h expressing HPV16 L2, peL1fB
expressing HPV18 L1, and peL2bhb expressing HPV18 L2
were gifts from J.T. Schiller. Four plasmids; p31L1h expressing
HPV31 L1, p31L2h expressing HPV31 L2, p58L1h expressing
HPV58 L1, and p58L2h expressing HPV58 L2 were newly
constructed by the replacement of the HPV16L1 gene in
p16L1h with the codon-modified HPV31L1, HPV31L2,
HPV58L1, and HPV58L2 genes, respectively. The codons
were changed to those used most frequently in human mRNAs;
Ala: GCC; Cys: TGC; Asp: GAC; Glu; GAG; Phe: TTC; Gly:
GGC; His: CAC; Ile: ATC; Lys: AAG; Leu: CTG; Asn: AAC;
Pro: CCC; Gln: CAG; Arg; AGG; Ser: AGC; Thr: ACC; Val:
GTG; Trp: TGG; Tyr: TAC.
Synthetic peptides
Peptides (Fig. 1) were synthesized by Fmoc method
(SCRUM Inc., Tokyo, Japan). C was added to the N-terminus
of P56/75, P61/75, P61/75(73V), P64/81, P-96/115, P96/115
(101L. 122S), and P-107/122 and to the C-terminus of P131/
144, respectively. The carrier protein, keyhole limpet hemo-
cyanin (KLH), was conjugated with P14/27 and P18/38 by
bisimide-ester method. KLH was conjugated with the other
peptides at the N- or C-terminus Cs of the peptides by the
m-maleimidobenzoyl-N-hydroxysuccinimide-ester method.
Rabbit anti-peptide serum
The peptide was conjugated with KLH at the cysteine
residue of each peptide. Japanese white rabbits (2.3–3.0 kg of
weight, 2 animals for each antigen) were subcutaneously
injected with the KLH conjugated peptide antigens mixed with
Freund's complete adjuvant (SCRUM Inc., Tokyo, Japan).
Immunization was repeated 4 times at 2-week interval, andserum was obtained at 1 week after the last immunization. The
antisera were filtered (Steradisc25, KURABO Inc., Osaka,
Japan) before use for the assays in this study.
Preparation of capsids
The recombinant baculoviruses capable of expressing
HPV16L1, HPV16L1/L2, HPV18L1/L2, HPV31L1/L2,
HPV58L1/L2 were produced by using Bac-to-Bac baculovirus
expression system (Invitrogen Corp., Carlsbad, CA), following
the manufacturer's instruction. The transfer vectors pFastbac1
was used for the cloning of the L1 gene, and pFastbac dual was
used for the cloning of both L1 and L2 genes. The recombinant
baculovirus was inoculated to Sf9 cells (5 bottles of 175 cm2
culture flask) and incubated for 3 days at 27 °C. The cells were
collected and suspended in 5 ml of PBS containing 0.5% NP-
40. After 10-min incubation at room temperature (RT), the cells
were centrifuged at 10,000×g at 4 °C for 15 min to precipitate
nuclei. The nuclei were suspended in PBS containing CsCl
(1.28 g/ml) and lysed with brief sonication. The solution was
centrifuged at 34,000 rpm at 20 °C for 20 h in an SW50.1 rotor
(BECKMAN COULTER Inc., Fullrerion, CA). The fractions
around a buoyant density of 1.28 g/ml were pooled and dialyzed
against phosphate buffer (pH7.4) containing 0.5 M NaCl at 4 °C
to remove CsCl.
ELISA with the L1 capsid of HPV16 and the L1/L2-capsids of
HPV16, 18, 31, and 58 as antigens
A well of the ELISA plate was coated with 100 μl of PBS
(pH 7.4) containing the purified L1 capsids (1 μg) or the L1/L2-
capsids (1 μg) by incubation for 14 to 16 h at 4 °C. The well was
blocked with 5% skim milk in PBS containing 0.1% Tween 20
for 2 h at 37 °C. After washing with PBS containing 0.05%
Tween 20 and 0.05% NP-40 three times, 100 μl of the serum
sample was added to the well and incubated for 1 h at RT. The
secondary antibody was horseradish peroxidase-conjugated
anti-rabbit IgG goat serum (SC-2030, Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA). A mixture of 0.01% H2O2 and o-
phenylenediamine (2 mg/ml) in 0.1 M citrate buffer (pH4.7)
was added to the wells and the absorbency at 450 nm was
measured after incubation for 30 min at 22 °C.
Preparation of pseudovirions
293TT cells, which had been seeded in a 10-cm culture dish
(4×106 cells) at 16 h before the transfection, were transfected
with a mixture of an L1-plasmid, an L2-plasmid, and pYSEAP
by using Optifect (Invitrogen Corp.). For HPV16, 31, and 58
pseudovirion production 13.5 μg of the L1-plasmid, 3 μg of
the L2-plasmid, and 13.5 μg of pYSEAP were used. For
HPV18 pseudovirion production 14.5 μg of the L1-plasmid,
1 μg of the L2-plasmid, and 14.5 μg of pYSEAP were used.
Sixty hours later the cells were harvested with trypsin. The
cells were suspended in 0.5 ml of lysis buffer (PBS containing
1 mM CaCl2, 10 mM MgCl2, 0.35% Brij58 [Sigma-Aldrich
Inc., St. Louis, MO], 0.1% Benzonase [Sigma-Aldrich Inc.],
271K. Kondo et al. / Virology 358 (2007) 266–2720.1% Plasmid Safe ATP dependent-DNase [EPICENTRE
Corp. Madison, WI]) and incubated for 30 h at 37 °C with
slow rotation. The lysate was cooled on ice for 5 min, mixed
with 5 M NaCl solutions to adjust to concentration of NaCl to
0.85 M, and further kept on ice for 10 min. Then, the lysate
was centrifuged at 5000×g for 10 min at 4 °C. The
supernatant was laid on an Optiprep gradient (from top to
bottom, 27%, 33%, and 39% in PBS containing 1 mM CaCl2,
10 mM MgCl2, and 0.8 M NaCl) and centrifuged at
50,000 rpm for 3.5 h at 16 °C with SW55Ti rotor (Beckman
Coulter Inc. Fullerton, CA). Fractions (300 μl each) were
obtained by puncturing the bottom. An aliquot (1 μl) of each
fraction was inoculated to 293TT cells (2×104) in 96-well flat-
bottom tissue culture treated plates (Corning Costar Corp.,
New York, NY). SEAP activity of the culture medium was
measured by the colorimetric SEAP assay (NCI home page:
http://home.ccr.cancer.gov/lco/colorimetricseap.htm). The frac-
tion induced the highest SEAP activity in the culture medium
of the cells was used for the neutralization test as a stock of the
infectious pseudovirions. To remove aggregates the pseudovir-
ion stock was filtered (Ultrafree-MC centrifugal Filter Devices,
MILIPORE corp., Bedford, MA) before use for the neutral-
ization assay.
Neutralization test
The serum was diluted with the neutralization medium
(DMEM [without phenol red] containing 10% FBS, 1% non-
essential amino acids, 1% GlutaMax-I). Fifty μl of a serum
sample was mixed with 50 μl of the neutralization medium
containing an aliquot of the pseudovirion stock (0.05 μl of
HPV16, 31, and 58 pseudovirions and 0.2 μl of HPV18
pseudovirions) and incubated for 1 h at room temperature.
Then, the mixture was inoculated to 293TT cells (2×104) that
had been seeded with 100 μl of the neutralization medium in 96-
well flat-bottom tissue culture plates 6 h prior to the inoculation.
The culture medium was harvested after incubation of the cells
for 66 h at 37 °C, and SEAP activity of the culture medium was
measured by the colorimetric SEAP assay. The neutralization
titer was presented as the reciprocal of maximum dilution of
serum that reduced SEAP level to half of the sample not treated
with serum.
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